Description: Destiny Pharma PLC is a United Kingdom-based clinical stage biotechnology company. The Company is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. The exeporfinium chloride (XF) Drug series is the Company’s anti-microbial drug platform and comprises the related XF and drugs described by Destiny Pharma (DPD) drug candidate. Its pipeline for the XF Drug products includes XF-73 Nasal, XF-73 Throat, XF-70 Dermal and XF-70 Lung. XF-73 is a synthetic dicationic porphyrin derivative with antibacterial activity. XF-73 is in the clinical development stage for the prevention of post-surgical staphylococcal infections. XF-73 has completed four Phase I /II A studies in Europe.
Home Page: www.destinypharma.com
DEST Technical Analysis
Sussex Innovation Centre
Brighton,
BN1 9SB
United Kingdom
Phone:
44 1273 704440
Officers
| Name | Title |
|---|---|
| Mr. Neil Robert Clark | CEO & Director |
| Dr. William Guy Love | Founder, Chief Scientific Officer & Director |
| Mr. Shaun Claydon ACA | CFO, Company Sec. & Director |
| Dr. Stephanie Bewick | Chief Bus. Officer |
| Dr. Yuri Martina M.B.A., M.D. | Chief Medical Officer |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2987 |
| Price-to-Sales TTM: | 181.8725 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 23 |